Modulation of CD4 Th cell differentiation by ganglioside GD1a in vitro

Journal of Immunology

Volumn 175, Issue 8, 2005, Pages 4927-4934

  Shen, Weiping ^a   Falahati, Rustom ^b   Stark, Ryan ^b   Leitenberg, David ^a,b   Ladisch, Stephan ^a,b  

^a CHILDREN S RESEARCH INSTITUTE   (United States)

^b GEORGE WASHINGTON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLERA TOXIN; GAMMA INTERFERON; GANGLIOSIDE; GANGLIOSIDE GD 1A; INTERLEUKIN 12; PERTUSSIS TOXIN;

ANTIGEN PRESENTING CELL; ARTICLE; CELL DIFFERENTIATION; CELL FUNCTION; CELL MATURATION; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DENDRITIC CELL; EFFECTOR CELL; HELPER CELL; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IN VITRO STUDY; PRIORITY JOURNAL; TH1 CELL; TH2 CELL; TUMOR IMMUNITY;

EID: 26844578733     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.175.8.4927     Document Type: Article

References (37)

1. Elgert, K. D., D. G. Alleva, and D. W. Mullins. 1998. Tumor-induced immune dysfunction: the macrophage connection. J. Leukocyte Biol. 64: 275-290.
2. Ladisch, S., B. Gillard, C. Wong, and L. Ulsh. 1983. Shedding and immunoregulatory activity of YAC-1 lymphoma cell gangliosides. Cancer Res. 43: 3808-3813.
3. Ladisch, S., and Z. L. Wu. 1985. Detection of a tumour-associated ganglioside in plasma of patients with neuroblastoma. Lancet 1: 136-138.
4. Chang, F., R. Li, and S. Ladisch. 1997. Shedding of gangliosides by human medulloblastoma cells. Exp. Cell Res. 234: 341-346.
5. Portoukalian, J., M. J. David, P. Gain, and M. Richard. 1993. Shedding of GD2 ganglioside in patients with retinoblastoma. Int. J. Cancer 53: 948-951.
6. Bernhard, H., K. H. Meyer zum Buschenfelde, and W. G. Dippold. 1989. Ganglioside GD3 shedding by human malignant melanoma cells. Int. J. Cancer 44: 155-160.
7. Ladisch, S., H. Becker, and L. Ulsh. 1992. Immunosuppression by human gangliosides. I. Relationship of carbohydrate structure to the inhibition of T cell responses. Biochim. Biophys. Acta 1125: 180-188.
8. McKallip, R., R. Li, and S. Ladisch. 1999. Tumor gangliosides inhibit the tumor-specific immune response. J. Immunol. 163: 3718-3726.
9. Ikeda, T., H. Nakakuma, H. Shionoya, T. Kawaguchi, K. Yamatsu, and K. Takatsuki. 1992. Ganglioside-induced inhibition of in vivo immune response in mice. Life Sci. 51: 847-851.
10. Caldwell, S., A. Heitger, W. Shen, Y. Liu, B. Taylor, and S. Ladisch. 2003. Mechanisms of ganglioside inhibition of APC function. J. Immunol. 171: 1676-1683.
11. Shen, W., and S. Ladisch. 2002. Ganglioside GD1a impedes lipopolysaccharide-induced maturation of human dendritic cells. Cell. Immunol. 220: 125-133.
12. Peguet-Navarro, J., M. Sportouch, I. Popa, O. Berthier, D. Schmitt, and J. Portoukalian. 2003. Gangliosides from human melanoma tumors impair dendritic cell differentiation from monocytes and induce their apoptosis. J. Immunol. 170: 3488-3494.
13. Shurin, G. V., M. R. Shurin, S. Bykovskaia, J. Shogan, M. T. Lotze, and E. M. Barksdale, Jr. 2001. Neuroblastoma-derived gangliosides inhibit dendritic cell generation and function. Cancer Res. 61: 363-369.
14. Ladisch, S., L. Ulsh, B. Gillard, and C. Wong. 1984. Modulation of the immune response by gangliosides: inhibition of adherent monocyte accessory function in vitro. J. Clin. Invest. 74: 2074-2081.
15. Heitger, A., and S. Ladisch. 1996. Gangliosides block antigen presentation by human monocytes. Biochim. Biophys. Acta 1303: 161-168.
16. Whisler, R. L., and A. J. Yates. 1980. Regulation of lymphocyte responses by human gangliosides. I. Characteristics of inhibitory effects and the induction of impaired activation. J. Immunol. 125: 2106-2111.
17. Bergelson, L. D., E. V. Dyatlovitskaya, T. E. Klyuchareva, E. V. Kryukova, A. F. Lemenovskaya, V. A. Matveeva, and E. V. Sinitsyna. 1989. The role of glycosphingolipids in natural immunity. Gangliosides modulate the cytotoxicity of natural killer cells. Eur. J. Immunol. 19: 1979-1983.
18. Rayman, P., A. K. Wesa, A. L. Richmond, T. Das, K. Biswas, G. Raval, W. J. Storkus, C. Tannenbaum, A. Novick, R. Bukowski, et al. 2004. Effect of renal cell carcinomas on the development of type 1 T-cell responses. Clin. Cancer Res. 10: 6360S-6366S.
19. Nishimura, T., M. Nakui, M. Sato, K. Iwakabe, H. Kitamura, M. Sekimoto, A. Ohta, T. Koda, and S. Nishimura. 2000. The critical role of Th1-dominant immunity in tumor immunology. Cancer Chemother. Pharmacol. 46(Suppl.): S52-S61.
20. + T cell responses in antitumor immunity. Curr. Opin. Immunol. 10: 588-594.
21. Banchereau, J., and R. M. Steinman. 1998. Dendritic cells and the control of immunity. Nature 392: 245-252.
22. Schuler, G., and R. M. Steinman. 1985. Murine epidermal Langerhans cells mature into potent immunostimulatory dendritic cells in vitro. J. Exp. Med. 161: 526-546.
23. Inaba, K., W. J. Swiggard, M. Inaba, J. Meltzer, A. Mirza, T. Sasagawa, M. C. Nussenzweig, and R. M. Steinman. 1995. Tissue distribution of the DEC-205 protein that is detected by the monoclonal antibody NLDC-145. I. Expression on dendritic cells and other subsets of mouse leukocytes. Cell. Immunol. 163: 148-156.
24. de Jong, E. C., P. L. Vieira, P. Kalinski, J. H. Schuitemaker, Y. Tanaka, E. A. Wierenga, M. Yazdanbakhsh, and M. L. Kapsenberg. 2002. Microbial compounds selectively induce Th1 cell-promoting or Th2 cell-promoting dendritic cells in vitro with diverse Th cell-polarizing signals. J. Immunol. 168: 1704-1709.
25. Ausiello, C. M., R. Lande, F. Urbani, B. Di Carlo, P. Stefanelli, S. Salmaso, P. Mastrantonio, and A. Cassone. 2000. Cell-mediated immunity and antibody responses to Bordetella pertussis antigens in children with a history of pertussis infection and in recipients of an acellular pertussis vaccine. J. Infect. Dis. 181: 1989-1995.
26. Xu-Amano, J., H. Kiyono, R. J. Jackson, H. F. Staats, K. Fujihashi, P. D. Burrows, C. O. Elson, S. Pillai, and J. R. McGhee. 1993. Helper T cell subsets for immunoglobulin A responses: oral immunization with tetanus toxoid and cholera toxin as adjuvant selectively induces Th2 cells in mucosa associated tissues. J. Exp. Med. 178: 1309-1320.
27. + T cells. J. Immunol. 154: 5071-5079.
28. De Smedt, T., M. Van Mechelen, G. De Becker, J. Urbain, O. Leo, and M. Moser. 1997. Effect of interleukin-10 on dendritic cell maturation and function. Eur. J. Immunol. 27: 1229-1235.
29. Lavelle, E. C., E. McNeela, M. E. Armstrong, O. Leavy, S. C. Higgins, and K. H. Mills. 2003. Cholera toxin promotes the induction of regulatory T cells specific for bystander antigens by modulating dendritic cell activation. J. Immunol. 171: 2384-2392.
30. Wolfl, M., W. Y. Batten, C. Posovszky, H. Bernhard, and F. Berthold. 2002. Gangliosides inhibit the development from monocytes to dendritic cells. Clin. Exp. Immunol. 130: 441-448.
31. Laderach, D., D. Compagno, O. Danos, W. Vainchenker, and A. Galy. 2003. RNA interference shows critical requirement for NF-κB p50 in the production of IL-12 by human dendritic cells. J. Immunol. 171: 1750-1757.
32. Rescigno, M., M. Martino, C. L. Sutherland, M. R. Gold, and P. Ricciardi-Castagnoli. 1998. Dendritic cell survival and maturation are regulated by different signaling pathways. J. Exp. Med. 188: 2175-2180.
33. Thornton, M. V., D. Kudo, P. Rayman, C. Horton, L. Molto, M. K. Cathcart, C. Ng, E. Paszkiewicz-Kozik, R. Bukowski, I. Derweesh, et al. 2004. Degradation of NF-κB in T cells by gangliosides expressed on renal cell carcinomas. J. Immunol. 172: 3480-3490.
34. Ranger, A. M., M. P. Das, V. K. Kuchroo, and L. H. Glimcher. 1996. B7-2 (CD86) is essential for the development of IL-4-producing T cells. Int. Immunol. 8: 1549-1560.
35. Freeman, G. J., V. A. Boussiotis, A. Anumanthan, G. M. Bernstein, X. Y. Ke, P. D. Rennert, G. S. Gray, J. G. Gribben, and L. M. Nadler. 1995. B7-1 and B7-2 do not deliver identical costimulatory signals, since B7-2 but not B7-1 preferentially costimulates the initial production of IL-4. Immunity 2: 523-532.
36. Schnurr, M., Q. Chen, A. Shin, W. Chen, T. Toy, C. Jenderek, S. Green, L. Miloradovic, D. Drane, I. D. Davis, et al. 2004. Tumor antigen processing and presentation depends critically on dendritic cell type and the mode of antigen delivery. Blood 105: 2465-2472.
37. Reichardt, V. L., P. Brossart, and L. Kanz. 2004. Dendritic cells in vaccination therapies of human malignant disease. Blood Rev. 18: 235-243.